May 2026 in “Journal of Skin and Sexually Transmitted Diseases” Upadacitinib effectively treats skin conditions like eczema and psoriasis and is becoming more widely used and affordable.
19 citations
,
April 2011 in “Headache The Journal of Head and Face Pain” Both topiramate and divalproex sodium effectively reduce migraine frequency and are generally well-tolerated.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
62 citations
,
November 2022 in “Acta Pharmaceutica Sinica B” The injectable hydrogel effectively speeds up chronic wound healing.
July 2025 in “Insights-Journal of Health and Rehabilitation” Adding vitamin D to metformin lowers blood sugar more than metformin alone in type 2 diabetes.
58 citations
,
May 2004 in “British Journal of Dermatology” Diphenylcyclopropenone treatment helps hair growth in alopecia areata by promoting blood vessel growth and cell survival.
8 citations
,
January 2023 in “Journal of Research in Pharmacy” Compounds from turmeric and bitter show strong potential as antiviral agents against the influenza A virus.
November 2024 in “Circulation” GLP1-RAs may have higher reports of suicide and hair loss, but no strong evidence links them to these issues.
9 citations
,
April 2020 in “Journal of Cosmetic Dermatology” Immune checkpoint inhibitors can cause scalp inflammation and hair follicle issues.
44 citations
,
October 2016 in “Epilepsia” 2-DG reduces seizures by enhancing brain inhibition through specific receptor activation.
8 citations
,
March 2023 in “PubMed” JAK inhibitors show promise in treating difficult skin diseases.
January 2022 in “SSRN Electronic Journal” Gemcitabine and Disitamab Vedotin effectively and safely reduced bladder cancer in a patient.
3 citations
,
May 2018 in “Reproductive Sciences” The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.
September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.
1 citations
,
July 2022 in “Frontiers in Pharmacology” Dutasteride may help protect neurons and reduce inflammation in Parkinson's disease.
September 2019 in “Journal of Investigative Dermatology” PCE-DP brightens skin and promotes hair growth by enhancing cell growth and reducing melanin uptake.
176 citations
,
June 2016 in “PLoS ONE” Nucleic acid polymers can enhance antiviral responses and improve treatment outcomes for chronic hepatitis B.
January 2026 in “Journal of Investigative Dermatology” 3D imaging effectively tracks skin changes in vitiligo treatment.
Individualized treatments may help manage Dercum's disease symptoms.
8 citations
,
January 2021 in “Journal of Pharmaceutical Investigation”
18 citations
,
September 2016 in “International Journal of Molecular Sciences” Polydeoxyribonucleotide (PDRN) may help lighten skin and treat hyperpigmentation.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
1 citations
,
August 2024 in “Journal of Pharmacy & Pharmaceutical Sciences” The DPCP/HPβCD complex improves solubility and anti-inflammatory effects for alopecia areata treatment.
August 2025 in “Journal of the American Academy of Dermatology”
18 citations
,
October 2017 in “Drug Design Development and Therapy” DA-9401 helps protect rat testis from finasteride damage.
January 2025 in “Fìzìologìčnij žurnal” PDRN may reduce inflammation and complications in revision rhinoplasty for patients with high fibrinogen levels.
7 citations
,
August 2000 in “Journal of Pediatric and Adolescent Gynecology” To improve use of the contraceptive DMPA among adolescents, effectively manage side effects like menstrual changes and weight gain through counseling and guidance.
July 2024 in “Journal of Investigative Dermatology” DS-2325a is safe and well-tolerated, supporting further development for Netherton Syndrome treatment.
1 citations
,
January 1989 in “Carcinogenesis” Dexamethasone reduces inflammation and delays skin cell changes caused by TPA.